Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 29.50
Change Today -0.80 / -2.64%
Volume 2.4M
As of 10:24 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

micromedic technologies ltd (MCTC) Snapshot

Open
$32.50
Previous Close
$30.30
Day High
$32.50
Day Low
$28.70
52 Week High
06/30/14 - $84.00
52 Week Low
12/30/14 - $15.60
Market Cap
21.9M
Average Volume 10 Days
1.2M
EPS TTM
$-0.28
Shares Outstanding
74.4M
EX-Date
06/9/03
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MICROMEDIC TECHNOLOGIES LTD (MCTC)

Related News

No related news articles were found.

micromedic technologies ltd (MCTC) Related Businessweek News

No Related Businessweek News Found

micromedic technologies ltd (MCTC) Details

Micromedic Technologies Ltd. develops and commercializes in vitro cancer diagnostic products and solutions in Israel. The company offers CellDetect, a technological platform for use in various cancer diagnostic applications, including cervical, bladder, and circulating tumor cells; and Colon MarCarePlex, a molecular biomarker assay that provides a non-invasive test for the detection of cancerous and pre-cancerous colorectal lesions. It also develops genetic assays for personalized medicine, including BRONJ, a risk assessment tool for medication-related osteonecrosis of the jaw; a functional gene expression profiling assay to identify carriers of deleterious BRCA mutations in women with breast cancer; and Lung Cancer Brain Metastases test, a gene expression profiling assay for identifying lung cancer patients that develop brain metastases. The company is based in Tel Aviv, Israel.

micromedic technologies ltd (MCTC) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 735.0K
Secretary
Total Annual Compensation: 175.0K
Compensation as of Fiscal Year 2014.

micromedic technologies ltd (MCTC) Key Developments

Micromedic Technologies Ltd to Form Joint Venture with BioRap Technologies Ltd

Micromedic Technologies Ltd. has entered into a joint venture agreement (JV) with BioRap Technologies Ltd., to develop and commercialize an early diagnostic device for diabetes on the basis of research conducted at the institute. Both the companies are based in Israel. The new JV will focus on developing and marketing a kit for the early detection of LADA diabetes (Latent Autoimmune Diabetes in Adults).

Micromedic Technologies Ltd, Special/Extraordinary Shareholders Meeting, Apr 02, 2015

Micromedic Technologies Ltd, Special/Extraordinary Shareholders Meeting, Apr 02, 2015., at 11:00 Israel Standard Time.

Micromedic Technologies Ltd Reports Successful Clinical Study Results for Monitoring Bladder Cancer Recurrence with the CellDetect® Non-Invasive Test

Micromedic Technologies Ltd. announced the results of a blinded, multi-center clinical study using the CellDetect® non-invasive technology to detect bladder cancer recurrence in patients with a history of the disease. The CellDetect® test successfully identified cancerous cells in urine samples, with reported sensitivity of 84.4% and specificity of 82.7% for the study's primary endpoint. The blinded clinical study was conducted in nine medical centers, where urine samples from 217 subjects with a history of bladder cancer were tested. The study population included 121 healthy subjects and 96 patients currently suffering from the disease. The results of the CellDetect® urine test were compared with results from biopsy or cystoscopy, in cases where biopsies were not performed. The results also indicated that the negative predictive value (NPV) was 98.5%. In addition to its high sensitivity for advanced stage tumors and high-grade malignancy, the test was also found to exhibit high sensitivity for early stage tumors and low-grade malignancies which are difficult to identify using other non-invasive tests currently available on the market. The secondary endpoint showed that the sensitivity of other non-invasive comparator tests, urine cytology, BTA stat and NMP22 BladderCheck, was 50.0%, 68.8% and 17.4%, respectively. These findings indicate that the method is adequately sensitive for the purpose of accurate and early detection of the recurrence of the disease. Following these successful study results, the company plans to secure a CE mark approval for a European launch of this non-invasive test later this year as well as to submit a Pre-IDE to the U.S. Food and Drug Administration (FDA).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MCTC:IT 29.50 -0.80

MCTC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MCTC.
View Industry Companies
 

Industry Analysis

MCTC

Industry Average

Valuation MCTC Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MICROMEDIC TECHNOLOGIES LTD, please visit www.m-medic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.